Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development.
Our mission is to help people see life better through medicine.
Successful EOP2 Meeting with FDA
We had a successful EOP2 meeting with the FDA for a disease modifying, first-in-class and first drug therapy to treat pterygium – a common ocular disease. In addition, we have strong IP protection with three issued patents from the United States Patent and Trademark Office (USPTO) to treat pterygium and hyperemia.